ABSTRACT
Introduction Cardiovascular disease (CVD) is a leading cause of death globally, responsible for nearly 18 million deaths worldwide in 2017. Medications to reduce the risk of cardiovascular events are prescribed based upon evidence from clinical trials which explore treatment effects in an indicated sample of the general population. However, these results may not be fully generalisable because of trial eligibility criteria that generally restrict to younger patients with fewer comorbidities. Therefore, evidence of effectiveness of medications for groups underrepresented in clinical trials such as those over 75 years, from ethnic minority backgrounds or with low kidney function may be limited.
The ONTARGET trial studied the effects of an angiotensin-converting-enzyme (ACE) inhibitor and an angiotensin II receptor blocker (ARB) separately and in combination on cardiovascular event reduction. Using individual anonymised data from this study, in collaboration with the original trial investigators, we aim to investigate clinical trial replicability within routinely-collected patient data. If the original trial results are replicable, we will assess treatment effects and risk in groups underrepresented and excluded from the original clinical trial.
Methods and analysis We will develop a cohort analogous to the ONTARGET trial within CPRD between 1 January 2001 to 31 July 2019 using the trial eligibility criteria and propensity score matching. The primary outcome, as in the trial, is a composite of cardiovascular death, non-fatal MI, non-fatal stroke and hospitalisation for congestive heart-failure, examined in a time-to-event analysis. If results from the cohort study fall within pre-specified limits, we will expand the cohort to include those with advanced kidney dysfunction and increase the proportion of elderly participants and those from ethnicity minority backgrounds.
We will then compare the risk of adverse events and association with long-term outcomes in the clinical trial, with that seen in a directly comparable sample of those attending NHS primary care.
Strengths
Large cohort study giving power to look at effects within subgroups underrepresented in the clinical trial
Access to individual patient level data from a landmark trial to support creation of a trial-analogous cohort
Novelty of studying treatment effects of dual therapy in real-world settings
Limitations
There may be differences between the trial population and the observational cohort due to the level of detail on inclusion/exclusion criteria provided by the trial
Drug-specific effects are unlikely to be able to be investigated due to small numbers in the dual-therapy arm: class-specific effects will be studied instead
Misclassification by primary care coding may lead to inaccurate replication of trial inclusion and exclusion criteria.
Competing Interest Statement
CC has received consultation, advisory board membership or research funding from the Ontario Ministry of Health, Sanofi, Pfizer, Leo Pharma, Astellas, Janssen, Amgen, Boehringer-Ingelheim and Baxter. In 2018 she co-chaired a KDIGO potassium controversies conference sponsored at arm's length by Fresenius Medical Care, AstraZeneca, Vifor Fresenius Medical Care, relypsa, Bayer HealthCare and Boehringer Ingelheim. She co-chairs the cloth mask knowledge exchange, a stakeholder group that includes cloth mask manufacturers and fabric distributors.
MC is an employee of, and own shares in, GSK.
Clinical Trial
No Clinical Trial ID as this is a protocol paper for a non-interventional study.
Funding Statement
This work is funded by a GlaxoSmithKline (GSK) sponsored PhD studentship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
An application for scientific approval related to the use of the Clinical Practice Research Datalink (CPRD) data has been approved by the Independent Scientific Advisory Committee of the Medicines and Healthcare Products Regulatory Agency in January 2020 (protocol no. 20_012). CPRD are already approved via a National Research Ethics Committee for purely non-interventional research if this type.
Ethical approval for this study has been obtained from the London School of Hygiene & Tropical Medicine Ethics Committee (Ref. 22658).
Access to the individual patient data from the ONTARGET trial has been obtained by the trial investigators via a data sharing agreement.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data was provided by CPRD under terms of the LSHTM license and can be requested from CPRD. ONTARGET trial data was obtained via a data sharing agreement with the sponsor, Hamilton Health Sciences Corporation.
